Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
de Bono, Johann, Lin, Chia-Chi, Chen, Li-Tzong, Corral, Jesus, Michalarea, Vasiliki, Rihawi, Karim, Ong, Michael, Lee, Jih-Hsiang, Hsu, Chih-Hung, Yang, James Chih-Hsin, Shiah, Her-Shyong, Yen, Chia-JLanguage:
english
Journal:
British Journal of Cancer
DOI:
10.1038/s41416-020-0774-1
Date:
March, 2020
File:
PDF, 709 KB
english, 2020